Literature DB >> 26730435

Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro.

Věra Králová1, Veronika Hanušová1, Emil Rudolf1, Kristýna Čáňová1, Lenka Skálová2.   

Abstract

OBJECTIVES: Flubendazole (FLU), a member of benzimidazole family of anthelmintic drugs, is able to inhibit proliferation of various cancer cells. The aim of present study was to elucidate the mechanisms of antiproliferative effect of FLU on colorectal cancer cells in vitro.
METHODS: The effect of FLU on proliferation, microtubular network, DNA content, caspase activation and senescence induction was studied in SW480 and SW620 cell lines. KEY
FINDINGS: Flubendazole significantly affected cell proliferation in a pattern typical for mitotic inhibitor. This was accompanied by decrease in cyclin D1 levels, increase in cyclin B1 levels, activation of caspase 2 and caspase 3/7 and PARP cleavage. Morphological observations revealed disruption of microtubular network, irregular mitotic spindles, formation of giant multinucleated cells and increase in nuclear area and DNA content. In SW620 cell line, 37.5% giant multinucleated cells induced by FLU treatment showed positivity for SA-β-galactosidase staining. Cell lines were able to recover from the treatment and this process was faster in SW480 cells.
CONCLUSION: Flubendazole in low concentration temporarily inhibits cell proliferation and induces mitotic catastrophe and premature senescence in human colon cancer cells in vitro.
© 2015 Royal Pharmaceutical Society.

Entities:  

Keywords:  benzimidazoles; colorectal cancer cells; flubendazole; mitotic catastrophe; senescence

Mesh:

Substances:

Year:  2016        PMID: 26730435     DOI: 10.1111/jphp.12503

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  16 in total

1.  Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis.

Authors:  Xumin Zhou; Jumei Liu; Jinming Zhang; Yong Wei; Hua Li
Journal:  Cell Death Discov       Date:  2018-02-14

2.  [Flubendazole Inhibits the Proliferation of A549 and H460 Cells and Promotes Autophagy].

Authors:  Tingjun Dong; Zejun Lu; Jingjiao Li; Yongzhen Liu; Juyi Wen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-05-20

3.  Carbonyl Reduction of Flubendazole in the Human Liver: Strict Stereospecificity, Sex Difference, Low Risk of Drug Interactions.

Authors:  Vladimír Kubíček; Lenka Skálová; Adam Skarka; Věra Králová; Jana Holubová; Jana Štěpánková; Zdeněk Šubrt; Barbora Szotáková
Journal:  Front Pharmacol       Date:  2019-05-28       Impact factor: 5.810

4.  Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.

Authors:  Zuzana Mrkvová; Stjepan Uldrijan; Antonio Pombinho; Petr Bartůněk; Iva Slaninová
Journal:  Molecules       Date:  2019-06-07       Impact factor: 4.411

5.  Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.

Authors:  Yongqi Zhen; Rongyan Zhao; Minjuan Wang; Xing Jiang; Feng Gao; Leilei Fu; Lan Zhang; Xian-Li Zhou
Journal:  Theranostics       Date:  2020-07-02       Impact factor: 11.556

Review 6.  Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System.

Authors:  Federica Laudisi; Martin Marônek; Antonio Di Grazia; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

Review 7.  Biology of Glioblastoma Multiforme-Exploration of Mitotic Catastrophe as a Potential Treatment Modality.

Authors:  Barbora Vitovcova; Veronika Skarkova; Kamil Rudolf; Emil Rudolf
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

8.  Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy.

Authors:  Rosalba Florio; Simone Carradori; Serena Veschi; Davide Brocco; Teresa Di Genni; Roberto Cirilli; Adriano Casulli; Alessandro Cama; Laura De Lellis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-17

9.  The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer.

Authors:  Rosalba Florio; Serena Veschi; Viviana di Giacomo; Sara Pagotto; Simone Carradori; Fabio Verginelli; Roberto Cirilli; Adriano Casulli; Antonino Grassadonia; Nicola Tinari; Amelia Cataldi; Rosa Amoroso; Alessandro Cama; Laura De Lellis
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

Review 10.  The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.

Authors:  Deok-Soo Son; Eun-Sook Lee; Samuel E Adunyah
Journal:  Immune Netw       Date:  2020-08-04       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.